A Superior Approach to Effective Drug Discovery

One Program Target > One Modulator > Multiple Therapeutic Applications

Alion is developing a pipeline of small molecule therapeutics targeting certain cancers and Central Nervous System diseases. Our therapeutics approach involves modulation of either protein-protein interactions or ion channels. In both instances, we have considerable experience and we have developed a proprietary computational means for the discovery of small molecules to modulate specific ion channel types.
Alion's technology dramatically reduces the time and cost of early stage drug development.
One Target>One Modulator>Multiple Therapeutics

Our Vision

From Lab to Cure

Using our proprietary computational means designed to reduce the time and cost of early stage drug development, we are building a pipeline of small molecule therapeutics targeting certain cancers and Central Nervous System (CNS) diseases.

Central Nervous System Diseases

Alois Alzheimer

Here we focus on protein-protein interactions. Several candidate molecules have been indentified.

Cancer

Our Progress

We currently have roughly 200 molecules in various stages of examination. Of those, 11 show great promise.

Join us
become an
Alion partner


Alion is interested in collaborative
pharmaceutical drug development
programs with appropriate partners

What's New?

27April

CNS Program News

Alion has identified a number of small molecules that modulate our therapeutic targets for new Alzheimer’s disease and other CNS therapeutics.

11March

Cancer Program News.

Alion has identified approximately 60 small molecules that modulate our therapeutic targets for new cancer therapeutics.

5March

Bright Future

As our principal programs to develop therapeutics to treat Alzheimer’s disease and glioblastoma multiforme have advanced, many new opportunities have emerged...

About Us

Alion Pharmaceuticals: built to create a better, faster approach to drug discovery and to create a pipeline of drugs aimed at a variety of cancers and at CNS diseases such as Alzheimers and Parkinsons.

Since the inception of our company, Alion has clearly demonstrated the "proof of concept" for our approach and programs. In planning Alion's progress, great emphasis has been placed on the mitigation of failure by maintaining parallel programs in oncology and CNS diseases. With this approach, it is reasonable to believe that the glioma program will reach the clinic first. However, therapeutics for Alzheimer's desease, Parkinson disease and other cancers are not far from clinical studies.

Alion programs for oncology and CNS therapeutics are attracting some considerable attention from major pharmaceutical companies with whom we may join in partner programs as we progress from early in vivo studies.